FDA grants AP status for Fentanyl-75 supplement by Difgen Pharms
The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for a supplement of Fentanyl-75 submitted by Difgen Pharmaceuticals.
Company
Pharmaceutical intelligence for Difgen Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.